Novo reports data breach, tells clinical trial patients to ‘remain vigilant’

As cybersecurity threats have proliferated across industries in recent years, biopharma companies have emerged as prominent targets, with intellectual property, patient data and other sensitive information at stake. Now, Novo Nordisk is the latest drug giant to report a data breach.

In a Thursday incident notice, Novo said it recently identified a security breach affecting certain internal IT systems, adding that “a limited amount of information related to patients participating in some of our clinical trials” had been exposed. 

As part of its investigation, the company found that certain data were “copied externally without authorisation,” according to the notice.

Read more at Fierce Pharma